Яков Шехтер

Яков Шехтер

Профессор Шехтер – один из самых авторитетных врачей онкологов в мире и ведущий специалист в  Израиле. Яков Шехтер является  основателем института исследования и лечения рака кожи Элла при МЦ Шиба, координатор уникальных исследований меланомы и системных онкологических заболеваний при помощи комбинирования хирургической, радиохирургической и биологической терапии.

Профессор Шехтер – автор большого числа научных статей на темы лечения меланомы и иммунологии опухолей, член группы ранних клинических исследований.

Образование, специализация

Точная диагностика на основании визуализации и результатов биопсии, клинические исследования.
Прогнозирование течение заболевания.
Остановка прогрессирования заболевания на «продвинутых» стадиях, индивидуальный подбор медикаментозной терапии как на основании результатов генетических анализов, так и на основании клинических показателей пациента.

  • Выпускник медицинского факультета Еврейского университета (Иерусалим)
  • Специализация по дерматоонкологии и радиотерапии в МЦ им. Рабина (Бейлинсон)

Ординатура

МЦ им. Рабина («Бейлинсон»), специализация: клиническая онкология и радиотерапия

Клинический опыт

  • Обширная практика работы по специальности в медицинском центре Ихилов-Сураски.
  • Ведущий специалист Израиля в лечении меланомы.

Членство в профессиональных организациях

  • Председатель форума Израильской ассоциации меланомы
  • EORTC (The European Organization for the Research and Treatment of Cancer)
  • Израильская ассоциация онкологии и клинической радиотерапии
  • Международное общество биотерапии

Научная деятельность

  • 2002-2003 Head Melanoma Forum, in ICOG
  • 2001-2003 Head of Melanoma Unit Rabin Medical Center (Beilinson Campus), Israel
  • 2001-2003 Deputy Chief Oncology Institute, Rabin Medical Center (Beilinson Campus), Israel
  • 1992 — 2003Member of Institutional Ethic Committee, Rabin Medical Center (Beilinson Campus), Israel
  • 2000-2003 Head of Inpatient Oncology Department, Rabin Medical Center (Beilinson Campus), Israel
  • 1992-2003 Senior investigator of new drugs ECSG-EORTC (Early Clinical Study Group — European Organization of Research and Treatment of cancer) and BRM clinical trials. Institute of Oncology, Beilinson Medical Center, Israel
  • 1986-2003 Principal investigator in clinical trials of interleukin-2 and melanoma vaccine. Institute of Oncology, Beilinson Medical Center, Israel
  • 1987 Senior oncologist, Institute of Oncology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
  • 1982-1986 Clinical co-investigator in immunotherapy trials of human cancer, Institute of Oncology, Beilinson Medical Center, Israel
  • 1981-1987 Resident in Medical Oncology and Radiotherapy Institute of Oncology, Beilinson Medical Center, Israel

Фиксированные достижения

1. Weinberger, O. Sperling, J. Schachter, U.A. Liberman, J. Pinkhas, A. DeVries. Urolithiasis associated with hypercalciuria. Int. Urol. Nephrol., 9:213, 1977.
2. Weinberger, J. Schachter, O. Sperling, U.A. Liberman, J. Pinkhas. Treatment with orthophosphosphate and hydrochlorothiazide for urolithiasis and idiopathic hypercalciuria. Urologia, 44:1, 1977.
3. Weinberger, J. Schachter, J. Pinkhas O. Sperling, Hereditary Hypercalciuric Urolithiasis. Brit. J. Urol, 53:285.1981.
4. Weinberger, J. Schachter, J. Pinkhas, O. Sperling. Metabolic and genetic aspects of idiopathic hypercalciuric urolothiasis. In: A. Weinberger, J. Schachter, J. Pinkhas O. Sperling, Vahlensieck (ed.) Advances in Urology and Nephrology. P.57, 1981.J. Barzilay, J. Schachter, E. Rakovsky, C. Mor. Coetaneous malignant lymphoma. Eur. J. Surg. Oncol., 11:337, 1985.
5. Adler, G. Gilon, H. Luria, J. Schachter, A Shani, C. Servadio, J. Stein. Active specific immunotherapy of renal carcinoma patients. J. Biol. Res. Modif., 6:610, 1987.
6. S. Aamdal, I. Wolff, S. Kaplan, R. Paridaens, J. Kerger, J. Schachter, J. Wanders, H.R Franklin, J. Verweij. Docetaxel in advanced malignant melanoma: a phase 2 study of the EORTC early clinical trials group. Eur. J. Cancer, 30/8:1061, 1994.
7. Sulkes, U. Beller, T. Peretz, J. Schachter, C. McDaniel, B. Winograd. Taxol: Initial Israeli experience with a novel anticancer agent. Isr. J. Med Sci., 30:70-78, 1994.
8. Adler, J. Schachter, Y. Barenholz, L.K. Bar, T. Klein, A. Sulkes, R. Michowiz, Y. Cohen, I. Kedar. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: Clinical and immunobiological effects. Cancer biother, 10(4):293-306, 1995.
9. Milo, G. Tamir, J. Sulkes, J. Schachter, D. Hauben. Epidemiology and prognostic factors in coetaneous malignant melanoma. Harefuah, 128:12, 1995 (Hebrew).
10. Klein, I. Levin, J. Schachter, H. Lurie, T. Klein, A. Siegel. The expression of CA-15-3 on breast cancer tumor cells in the serum in relation to survival.Cell Vision, 2:455-457, 1995.
11. T. Klein, I. Levin, A. Niska, R. Koren, R. Gal, J. Schachter, R. Narinski, B. Klein. Correlation between tumor and serum ß2m, expression in patients with breast cancer. Eur. J. Immunogenet., 23:417-423, 1996.
12. J. Schachter, T. Klein, B. Klein, A. Adler. HLA class I and advanced melanoma in Israel Jews. Int. J. Oncol., 10(3):645-648, 1997.
13. J. Schachter, E. Rakowsky, A. Sulkes, A. Adler. Sequential four drug chemotherapy program and biotherapy with interferon alpha and GM-CSF. Cancer Biother. Radiopharma., 13:155-164, 1998.
14. M. Mishaeli, B. Klein, E. Sadikov, I. Bayer, R. Koren, R. Gal, E. Rakowsky, I. Levin, B. Kfir, J. Schachter. Initial TPS serum level as an indicator of relapse and survival in colorectal cancer. Anticancer Res., 18:2101-2106, 1998.
15. E. Fenig, E. Eidelevich, E. Njugona, A. Katz, H. Gutman, A. Sulkes, J. Schachter. The role of radiation therapy in the management of coetaneous malignant melanoma. Am. J. Clin. Oncol., 22(2):184-186, 1999.
16. J. Schachter, B. Brenner, E. Fenig, J. Yahav, G. Marshak, A. Sulkes, H. Gutman.
17. Brenner, E. Rakowsky, A. Katz, H. Gutman, A. Sulkes, J. Schachter, E. Fenig.
Tailoring Treatment for Classical Kaposi Sarcoma: Comprehensive Clinical Guidelines.
Int. J. Oncol., 14:1097-1102, 1999.
18. J. Schachter, A.L. Vaturi S. Mekhmandarov, M. Feinmesser, F. Fening, G. Tamir, H.
Gutman. Standard and nonstandard applications of sentinel node guided melanoma
Surgery. World J. Surg.,24:491-495, 2000.
19. N. Wasserberg, J. Schachter, E. Fening, M. Feinmesser, H. Gutman. Merkel Cell
Carcinoma, a Plea for Application of the Sentinel Node Technique. Dermatologic
Surgery, 26:138-141, 2000.
20. R. Paridaens, L. Biganzoli, P. Bruning, J.G.M Klijn. T. Gamucci, S. Houston, R.
Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, A. Awada, J. Wildiers, M. Piccart. Taxol Versus Doxorubicin as First-Line Single Agent Chemotherapy for Metastatic Breast Cancer – An EORTC Randomized Study with Crossover. J. Clin. Oncol, 18: 724-733, 2000.
21. Fenig, B. Brener, E. Njuguna, A. Katz, J. Schachter, A. Sulkes. Oral etoposide for Merkel cell carcinoma in patients previously treated with intravenous Etoposide. Am. J. Clin. Oncol. 23(1):65-67, 2000.
22. Fenig, B. Brenner, A. Katz, J. Sulkes, M. Lapidot, J. Schachter, H. Melik, A. Sulkes, H. Gutman. Topical Biafine and Lipiderm for the prevention of radiation dermatitis: A randomized prospective trial. Oncology Rep. 8: 305-309, 2001.
23. H. Gutman, J. Schachter, E. Stopel, R. Gutmen, J. Lahav. Impaired platelet aggregation in melanoma patients treated with Interferon-α-2b adjuvant therapy. Cancer. 94: 780- 785, 2002.
24. M. Feinmesser, J. Schachter, A. Tobar, J. Sulkes, H. Gutman, N. Kruk, E. Okon. Relations of tumorigenic malignant melanoma to dermal elastin. Am. J. Dermatopathol. 24(2): 108-117, 2002.
25. T. Waserberg, S. Morgenstern, J. Schachter, E. Fenig, S. Lelcuk, H. Gutman. Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component. Arch Surg. 137: 1249-1252, 2002.
26. J. Schachter, B. Brenner, E. Fenig, R. Gutman, A. Sulkes, H. Gutman. Patterns of failure in patients with malignant melanoma treated with high dose Interferon-α-2b in the adjustment setting. Melanoma Res. 13: 93-96, 2003.
27. Brenner, S. Borok, E. Rakowsky, E. Fenig, H. Gutman, J. Sulkes, A. Sulkes, J. Schachter. Older age and second skin cancer as prognostic factors in localized malignant Melanoma. Oncology Rep. 10(6) :2051-2057, 2003.
28. Brenner, L. Wasserman, E. Beery, J. Nordenberg, J. Schachter, H. Gutman, E. Fenig. Variable cytotoxicity of amifostine in malignant and non-malignant cell lines. Oncology Rep. 10: 1609-1613, 2003.
29. H. Gutman, J. Schachter, N. Wasserberg, I. Shechtman, F. Greiff. Are solitary breast papilomas entirely benign? Archive Surg. 138:1330-1333, 2003.
30. T. Menes, J. Schachter, S. Morgenstern, E. Fenig, H. Lurie, H. Gutman. Primary Squamous Cell Carcinoma (SqCC) of the Breast. Am. J. Clin. Oncol. 26:571-573, 2003.
31. N. Wasserberg, H. Tulchinsky, J. Schachter, M. Feinmesser, H. Gutman.Sentinel- lymph-node biopsy (SLNB) for melanoma is complication-free.Euro J Surg Oncol. 30:851-856, 2004.
32. T. Shpitzer, K. Segal, J. Schachter, R. Hardoff, D. Guttman, D. Ulanovski, R. Feinmesser, H. Gutman. Sentinel node guided surgery for melanoma in the head and neck region. Melanoma Res. 14: 283-287, 2004.
33. T.S. Mennes, J. Schachter, A.P. Seinmetz, R. Hardoff, H. Gutman. Lymphatic Drainage to the Popliteal Basin in Distal Lower Extremity Malignant Melanoma.Arch Surg. 139: 1002-1006, 2004.
34. Marshak, E. Rakowsky, J. Schachter, J. Shvero, R. Feinmesser, A. Sulkes, B. Brenner. Is the delay in starting postoperative radiotherapy a key factor in the outcome of advanced (T3 and T4) laryngeal cancer? Otolaryngology – Head and Neck Surgery. 131: 489-493, 2004.
35. N. Nathansohn, J. Schachter, H. Gutman. Patterns of Recurrence in Patients with Melanoma after Radical Lymph Node Dissection. Arch Surg. 140:1172-1177, 2005.
36. M.J. Besser, A.J. Treves, O. Itzhaki, I. Hardan, A. Nagler, M.Z. Papa, R. Catane, E. Winkler, B. Shalom-Zifroni, J. Schachter. Adoptive Cell Therapy for Metastatic Melanoma Patients Pre-clinical development at the Sheba Medical Center. IMAJ 8:164- 168, 2006.
37. G Markel, R. Seidman, N. Stern, T. Cohen-Sinai, O. Izhaki, G. Katz, M. Besser, AJ.Treves, RS.Blumberg, R. Loewenthal, O. Mandelboim, A. Orenstein, and J. Schachter. Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by. J Immunol.; 177: 6062-6071, 2006.
38. Y. Hamama,Raz, Z. Solomon, J. Schachter, E. Azizi. Objective and subjective stressors and the psychological adjustment of melanoma survivors. Accepted for publication. Psychooncology. 2007 Apr;16(4):287-294.
39. J .Schachter, U Katz, A Mahrer, D Barak, LZ David, J Nusbacher, Y Shoenfeld. Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann N Y Acad Sci. 2007 Sep;1110:305-314.
40. N Nathansohn, A Orenstein, H Trau, A Liran, J Schachter. Pigmented lesions clinic for early detection of melanoma: preliminary results. Isr Med Assoc J. 2007 Oct;9(10):708- 712.
41. GI Keshet, I Goldstein, O Itzhaki, K Cesarkas, L Shenhav, A Yakirevitch, AJ Treves, J Schachter, N Amariglio, G Rechavi. MDR1 Expression Identifies Human Melanoma Stem Cells. Biochem Biophys Res Commun. 2008 Apr 18;368(4):930-6
(IF – 2.749 Biophysics 27/69)
42. E Schallmach, R Sareli, MJ Besser, S Leipsiger, I Hardan, AJ Treves, A Nagler, J Schachter.
Collection of Large-Scale Expanded Lymphocyte Cultures for Adoptive Immunotherapy Using a COBE Spectra Apheresis Machine. J Immunother. 2008;
31(6):563-8
( IF-4.873 Medicine, Research & Experimental 8/81 )
43. E Soudry, H. Gutman, M Feinmesser, R Gutman, J Schachter. «Gloves-And-Socks»
Melanoma: Does Histology Make a Difference? Dermatol Surg. 2008 Oct;34(10):1372-8.
(IF- 1.769 Surgery 45/139)
44. J Bar, R Yerushalmi, R Shapira-Frummer, I Kutchuk, A Sulkes, H Gutman, R Catane, J Schachter. Concurrent Chemobiotherapy with Cisplatin, Dacarbazine, Decrescendo Interleukin-2 And Interferon Alpha2b In Patients with Metastatic Melanoma. Oncol Rep. 2008 Dec;20(6):1533-8.
(IF-1.597 Oncology 97/132)
45. G Markel, T Cohen-Sinai, MJ Besser, K Oved, O Itzhaki, R Seidman, E Fridman, AJ Treves, Y Keisari, Z Dotan, J Ramon, J Schachter. Preclinical Evaluation of Adoptive
46. G Markel, R Seidman, Y Cohen, MJ Besser, TC Sinai, AJ Treves, A Orenstein, R Berger, J Schachter. Dynamic Expression of Protective CEACAM1 on Melanoma Cells During Specific Immune Attack. Immunology. 2009 Feb;126(2):186-200.
(IF-3.398 Immunology 38/119)
47. M.J. Besser, E. Schallmach, K. Oved, A.J. Treves, G. Markel, Y. Reiter, J. Schachter.
Modifying IL-2 Concentrations During Culture Improves Function Of T-Cells For Adoptive Immunotherapy. Cytotherapy. 2009;11(2):206-17
(IF-3.553 Biotechnology & Applied Microbiology 26/138)
48. MJ Besser, R Shapira-Frommer, AJ Treves, D Zippel, O Itzhaki, E Schallmach, A Kubi, B Shalmon, I Hardan, R Catane, E Segal, G Markel, S Apter, AB Nun, I Kuchuk, A Shimoni, A Nagler, J Schachter. Minimally Cultured Or Selected Autologous Tumor- Infiltrating Lymphocytes After A Lympho-Depleting Chemotherapy Regimen In Metastatic Melanoma Patients. J Immunother. 2009 May;32(4):415-23.
(IF-4.873 Immunology 17/119)
49. J Mashiah, S Brenner, K Pessach, V Barak, J Schachter. Differences In Cytokine Levels In Melanoma Patients With And Without Redness (Brenner Sign) Anticancer Res. 2009 May;29(5):1793-6.
(IF-1.597 Oncology 108/132)
50. K Oved, E Eden, M Akerman, R Noy, R Wolchinski, O Izhaki, E Schalmmach, A Kubi, N Zabari, J Schachter, U Alon, Y Mandel- Gutfreud, MJ Besser, Y Reitr. Predicting and Controlling the Reactivity of Immune Cell Populations Against Cancer. Mol Syst Biol. 2009;5:265.
(IF 9.954 Biochemistry & Molecular Biology 16/263)
This Article Was Selected Editor’s Choice At Science 8 May 2009: 693
51. G. Markel, R Seidman, MJ Besser, N Zabari, R Ortenberg, R Shapira, AJ Treves, R Loewenthal, A Orenstein, A Nagler, J Schachter. Natural Killer Lysis Receptor (NKLR)/NKLR-Ligand Matching as a Novel Approach for Enhancing Anti-Tumor Activity of Allogeneic NK Cells. PLoS ONE. 2009;4(5):e5597.
52. I Gluck, AJ Simon, R Catane, R Pfeffer, J Schachter, G Rechavi, J Bar, Germline analysis of Thymidine/Guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients. Melanoma Research. 2009 Aug;19(4):199-202. (IF-2.225 Dermatology 10/41)
53. DB Zippel, R Shapira, I Kuchuk, D Goiten, A Winkler, MZ Papa, J Schachter. Outcome of thick, node negative melanomas. IMAJ. 2009 November;9:669-672.
(IF -0.577 Medicine, General & Internal 75/100)
54. Markel G. Bar J. Seidman R. Sapoznik S.Ortenberg R. Besser MJ. Shapira R. Kubi A. Nardini G. Tissone A. Treves AJ. Winkler E. Orenstein A.
Schachter J. Systemic dysregulation of CEACAM1 in melanoma patients. 2010. Cancer Immunol. Immunother. 2010;59:215-230.
(IF-3.728 Immunology 33/119)
55. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A and Schachter J. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-Term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clin Cancer Res 2010:16[9]:2646-2655.
(Oncology 14/141, IF 6.646)
56. Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S,Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N, Markel G. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6(4):e18936, 2011.
57. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Traves AJ, Shalmon B, Zippel D, Markel D, Shapira-Formmer R, Shachter J, Besser MJ. Establishment and large-scale expansion of minimally cultured «young» tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 34(2):212-220, 2011.
58. Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisary Y, Besser MJ, Schachter J, Shomron N, Markel G. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6(4):e18936, 2011.
59. Greenberg E, Rechavi G, Amariglio N, Solomon O, Schachter J, Markel G, Eyal E. Mutagen-specific mutation signature determines global microRNA binding. PLoS One 6(11):e27400, 2011.
60. Greenberg E. Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One 6(4):e18936, 2011.
61. Sapoznik S, Faranesh S, Ortenberg R, Hamburger T, Barak V, Peretz T, Schachter J, Markel G, Lotem M. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol 2011, in press.
62. Khatib N, Pe’er J, Ortenberg R, Schachter J, Frenkel S, Markel G, Amer R. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: Correlation with clinical and histological survival markers. Invest Opthal Vis Sci 52(13):9368-9372, 2011.
63. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, nelson B, Hou J, lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516, 2011.
64. Sapoznik S, Ortenberg R, Schachter J, Markel G. CEACAM1 in malignant melanoma: A diagnostic and therapeutic target. Curr Top Med Chem 12(1):3-10, 2012.
65. Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovsky, Levy D, Cohen CJ, Besser MJ, Schachter J, Markel G. CXCR1 as a novel target for directing reactive T cells towards melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother 61(10):1833-1847, 2012.
66. Ortenberg R, Sapir Y, Raz L, Hershkovitch L, Ben-Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Molecular Cancer Therapeutics 11(6):1300-1310, 2012
67. Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Scjacjter K. Markel G. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012:818214, 2012.
68. Sapoznik S, farancesh S, Ortenberg R, Hamburger T, Barak V, Peretz T, Schachter J, Markel G, Lotem M. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol 2012, in press.
69. Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, Van Rooij N, Linnemann C, Van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA,
Haanen JB, Hadrup SR, Schumacher TN. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1(4):409-418, 2012.
70. Gutman H, Ben-Ami E, Shappira-Frommer R, Schachter J. Multidisciplinary management of very advanced stage III and IV melanoma: Proof-of-principle. Oncol Lett 4(2):307-310, 2012.
71. Shapira-Frommer R, Schachter J. Adoptive immunotherapy of advanced melanoma. Curr Treat Options Oncol 13(3):340-353, 2012.
72. Zippel DB, Besser M, Shapira R, Ben-Nun A, Goitein D, Davidson T, Treves AJ, Markel G, Schachter J, Papa MZ. Adoptive cell therapy with autologous tumor- infiltrating lymphocytes and hig-dose interleukin-2 for metastatic melanoma: The surgeon’s perspective. Exp Ther Med 3(5):898-902, 2012.
73. Vernitsky H, Rechavi O, Rainy N, Besser MJ, Nagar M, Schachter J, lerenthal Y, Ehrilich M, Kloog Y, Goldstein I. Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functions. J Immunol 189(9):4361-4370, 2012.
74. Sivan S, Sizam F. Rona O, Tamar H, Vivian B, Tamar P, Jacob S, Gal M, michal L. Serum CEACAM1correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol 2012:290536, 2012.
75. Sivan S, Suzan F, Rona O, Tamar H,Vivian B, Tamar P, Jacob S, Gal M, Michal L. Serum CEACAM1 correlates with disease progression and survival in maligmant melanoma patients. Clin Dev Immunol 2012:290536, 2012.
76. Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J, Besser MJ. Adoptive T-cell transfer in melanoma. Immunotherapy 5(1):79-90, 2013.
77. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparting tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616-622, 2013.
78. Klein M, Lotem M, Peretz T, Zwas ST, Mizrachi S, Liberman Y, Chisin R, Schachter J, Ron IG, Iosilevsky G, Kennedy JA, Revskaya E, de Kater AW, Banaga E, Klutzaritz V, Friedmann N, Galun E, Denardo GL, Denardo SJ, Casadevall A, Dadachova E, Thornton GB. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer 2013:828329, 2013.
79. Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E, Schachter J, Besser MJ, Markel G. Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One 8(2):e57160, 2013.
80. O’Dady SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L,
Robert C, Schachter J, Testori A, mackiewicz J, Friedlander P, Garber C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, hauschild A. Final results of phase III Symmetry study: Randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment of chemotherapy-naïve patients with advanced melanoma. J Clin Oncol 31(9):1211-1218, 2013.
81. Besser MJ, Shoham T, Harari-Steinberg O, Zabari N, Ortenberg r Yakirevitch A, Nagler A, Loewenthal R, Schachter J, Markel G. Development of allgeneic NK cell adoptive transfer therapy in metastatic melanoma patients: In vitro preclinical optimization studies. PLoS One 8(3):e57922, 2013.
82. Zikich D, Schachter J, Besser MJ. Immunotherapy for the management of advanced melanoma: The next steps. Am J Clin dermatol 14(4):261-272, 2013.
83. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel D, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J. Adoptive transfer of tumor infiltrating lymphocytes in metastatic melanoma patients: Intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19(17):4792-4800, 2013.
84. Nemlich Y, Greenberg e, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J,
Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest 123(6):2703-2718, 2013.
85. Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, Levi D, Kubi A, Eyal E, Onn A, Cohen Y, Barshack I, Schachter J, Markel G. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: A pilot study. Biomarkers. 18(6):502-508, 2013.
86. Larkin J, del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandala M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: An open-lebel, multicenter, safety study. Lancet Oncol 15(4):436-444, 2014.
87. Shrot S, Schachter J, Shapira-Frommer R, Besser MJ, Apter S. CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases. Eur Radiol 24(6):1251-1256, 2014.
88. Wainstein A, Algarra SM, Bastholt L, Cinat G, Demidov L, Grob JJ, guo J, Hersey P, Espinosa E, Schachter J, Whitaker D, Quirt I, Hauschild A, rutkowski P. Melanoma early detection and awareness: How countries developing melanoma awareness programs could benefit from melanoma-proficient countries. Am J Ther 2014, in press.
89. Greenberg E, Hajdu S, Nemlich Y, Cohen R, Itzhaki O Jacob-Hirsch J, Besser MJ, Schachter J, Markel G. Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biol 4(6):140030, 2014.
90. Ortenberg R, Galore-Haskel G, Greenberg I, Zamlin B, Sapoznik S, Greenberg E, Barshack I, Avivi C, Feiler Y, Zan-Bar I, Besser M, Azizi E, Eitan F, Schachter J, Markel G. CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia .2014 ,451-460:)5(16
91. Greenberg GI, Zamlin B, Sapoznik S, Greenberg E, Barshack I, Avivi C, Feiler Y, Zan- Bar I, Besser MJ, Azizi E, eitan F, Schachter J, Markel G. CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia 16(5):451-460, 2014.

Книги

1. J. Schachter, A. Weinberger, J. Pinkhas, O. Sperling. Familial hypercalciuric urolithiasis. In: Urolithiasis: Clinical and basic Research, Plenum Press, NY p. 21, 1981
2. J. Schachter. Fever in Oncology.
In: B. Isaac, M. Burke, S. Kerenbaum (eds.) Unexplained Fever. CRC Press p. 381, 1991
3. J. Schachter, A. Laish, S. Mekhmandarov, M. Feinmesser, H. Gutman. Standard and nonstandard application of SNB guided melanoma surgery.
In: Year Book of Dermatology, MOSBT – Year Book INC 2001

departments: Онколог
positions: Онколог

Запись на приём